Preclinical News and Research

RSS

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Viking Systems' first-quarter 2010 sales up 26%

Viking Systems, Inc. today announced financial results for its first quarter ended March 31, 2010. The Company reported a 26% increase in sales to $1,915,073 for the quarter ended March 31, 2010 and a net loss of $295,450 or ($0.01) per share.

5 May 2010

Micromet reports total revenues of $6.3 million for first-quarter 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2010.

5 May 2010

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring StemCells Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

MicroStockProfit.com: CRXX's total revenues reach $8.6M in fourth-quarter 2009

MicroStockProfit.com announces an investment report featuring CombinatoRx Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

Algal DHA improves memory function in healthy aging adults: MIDAS

The Memory Improvement with Docosahexaenoic acid Study published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.

4 May 2010

Informative session on TP-drug interactions

AAPS is pleased to present the workshop on Strategies to Address Therapeutic Protein Drug Interactions during Clinical Development. This event will feature a review of pre-clinical tools, test systems, and relevant documented Therapeutic Protein-drug interactions.

4 May 2010

Preclinical News and Research

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Viking Systems' first-quarter 2010 sales up 26%

Micromet reports total revenues of $6.3 million for first-quarter 2010

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com: CRXX's total revenues reach $8.6M in fourth-quarter 2009

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Celldex reports net loss of $6.6 million for first-quarter 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

MicroStockProfit.com releases investment report on Vical

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

Algal DHA improves memory function in healthy aging adults: MIDAS

Informative session on TP-drug interactions

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics